Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S. Alsubhi N, et al. Among authors: curtin nj. Mol Oncol. 2016 Feb;10(2):213-23. doi: 10.1016/j.molonc.2015.09.009. Epub 2015 Oct 3. Mol Oncol. 2016. PMID: 26459098 Free PMC article.
PARP inhibitors for cancer therapy.
Curtin NJ. Curtin NJ. Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. doi: 10.1017/S146239940500904X. Expert Rev Mol Med. 2005. PMID: 15836799 Review.
Targeting the S and G2 checkpoint to treat cancer.
Chen T, Stephens PA, Middleton FK, Curtin NJ. Chen T, et al. Among authors: curtin nj. Drug Discov Today. 2012 Mar;17(5-6):194-202. doi: 10.1016/j.drudis.2011.12.009. Epub 2011 Dec 15. Drug Discov Today. 2012. PMID: 22192883 Review.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ. Munck JM, et al. Among authors: curtin nj. Mol Cancer Ther. 2012 Aug;11(8):1789-98. doi: 10.1158/1535-7163.MCT-11-0535. Epub 2012 May 10. Mol Cancer Ther. 2012. PMID: 22576130 Free PMC article.
Development of pharmacodynamic biomarkers for ATR inhibitors.
Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ. Chen T, et al. Among authors: curtin nj. Mol Oncol. 2015 Feb;9(2):463-72. doi: 10.1016/j.molonc.2014.09.012. Epub 2014 Oct 13. Mol Oncol. 2015. PMID: 25459351 Free PMC article.
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. Abdel-Fatah TM, et al. Among authors: curtin nj. Mol Oncol. 2015 Mar;9(3):569-85. doi: 10.1016/j.molonc.2014.10.013. Epub 2014 Nov 6. Mol Oncol. 2015. PMID: 25468710 Free PMC article.
189 results